الفهرس 
Introduction and Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Continence is a critical parameter in the evaluation of the functional success of an orthotopic bladder substitute. It depends on the balance between the pressure within the reservoir and the urethral closure ;: pressure. Inspite of the construction of detubularized low-pressure! reservoirs, neobladders anastomosed to the urethra still are not ideal, with approximately 20-30% of the pat,ients experiencing nocturnal incontinence. Many drugs belonging to different pharmacologic groups have potential benefits in manipulating different intestinal reservoirs but few were tried.. ~ Twenty enuretic male patIents wIth orthotopIC Ileal reserVOIrS ~ (HemiKock or ”W” neobladders) were clinically and urodynamically evaluated before being enrolled in this prospective randomized crossover study to compare the clinical and urodynamic effect of oxybutinin versus ~: verapamil in the treatment of nocturnal enuresis. I ,; Both drugs clinically improved the continence status of the patients in the form of either decrease in the number of pads used per night or the frequency of wetting episodes per week. This improvement occurred in 70% of patients after oxybutinin and in 55 0:-0 after verapamil. Both drugs significantly increased the mean volume at first desire (from 275:1:91.5 ml to 394.6:t158.3 ml after oxybutinin and to 346.4:t142.9 ml after verapamil), the mean volume at normal desire (from 408:t142.5 ml to 495.5:t172.6 ml after oxybutinin and to 465.1:t156.4 ml after verapamil) and the mean maximum enterocystometric capacity (from 585:t148.6 ml to 667.5:t180.8 ml after oxybutinin and to 62.1.05:t 170.5 ml after verapamil). Inspite of this, there was no significant change of the pressures at the same parameters except the basal pressure at maximum enterocystometric capacity after verapamil, which significantly decreased from (20.1:t8.3 cmH20) to (16.07:t5.1 cmH20). The number of uninhibited contractions in the last five minutes of filling significantly decreased from (3.6:t0.7) to (1.9:t1.2) after oxybutinin and to (2.1:t1.26) after verapamil. The amplitude of maximum uninhibited contraction decreased from (41.15:t9.1 cmH20) to (34.?5:t12.77 cmH20) after oxybutinin and to (33.25:t11.52 cmH20) after verapamil. Both drugs